Study Summaries
GOG 218: Bevacizumab in Front-Line Ovarian Cancer
GOG-278: Nonradical Surgery — QOL and Physical Function in Early-Stage Cervical Cancer
Publications Update # 132
Fate of the IP chemotherapy and now the HIPEC chemotherapy, Mirvetuximab + Bevacizumab in ovarian cancer, should we resect para-aortic nodes in locally advanced cervical cancer (video)
PEACOCC: Pembrolizumab in Advanced Clear Cell Gynecological Cancer
Pembrolizumab demonstrated clinical benefit in heavily pretreated advanced CCGC with a tolerable safety profile. Further evaluation in a randomized trial is warranted.
LARA: Pembrolizumab plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma
Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.
GOG 3026: Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Ovarian Carcinoma
LACC: Open vs. MIS in Radical Hysterectomy (Final OS)
Minimally invasive radical hysterectomy results in inferior DFS and OS compared to open surgery and is associated with higher recurrence and carcinomatosis. Open surgery should remain the standard of care.
GOG 71: RT +/- Extrafascial Hysterectomy
Routine adjuvant extrafascial hysterectomy after radiation for bulky stage IB cervical carcinoma did not improve OS. Some benefit in local control and PFS was observed, particularly in patients with tumors 4–6 cm.
RAMP-201
Avutometinib 3.2 mg BIW + defactinib 200 mg BID (3-weeks-on/1-week-off) produced clinically meaningful and durable responses with manageable toxicity in recurrent LGSOC